Public Policy Resources

Representation is important to cancer patients and survivors when it comes to the composition of clinical trials, with patients saying it is important that drugs are tested among patients who share their gender, age, and general health. Women consider it more important that drugs be tested in patients who share their gender than do men, while people of color are most concerned about representation in clinical trials.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) Draft Guidance on Decentralized Clinical Trials. 

These consensus recommendations endorsed by 12 organizations identify key steps to improve equitable pharmacogenomic (PGx) discovery and  implementation in oncology.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on Pharmacogenomic Data Submissions Draft Guidance for Industry. 

By focusing explicitly on bold, transformative, and applied research projects, ARPA-H holds the potential to quickly bridge the gap between the research lab and the patient. 

ACS CAN was joined by 22 other organizations in proposing the HHS Office of Inspector General (OIG) adopt a new regulatory safe harbor from the Anti-kickback Statute (AKS) that would allow clinical trial sponsors to financially support patients to offset extra non-medical costs associated with cl

Pharmacogenomic (PGx) testing is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body. 

As part of his renewed Cancer Moonshot initiative, President Biden has set the goal of reducing cancer deaths by 50% by 2050. ACS and ACS CAN are committed to helping achieve that goal by tackling cancer at every angle.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry.